(negatively selected) were obtained by collecting the supernatants. The resulting cell populations consistently contained at least 97% B lymphocytes, as assessed by double staining with the Leu 1 (CDS) and Leu 12 (CD19) MoAbs, both from Becton Dickinson (Mountain View, CA).'.'" MNC were also isolated from surgically removed tonsils and depleted of T cells, macrophages, and natural killer (NK) cells as previously described; these cell fractions consistently contained higher than 95% CD19' B cells. Tonsillar B cells were subsequently fractionated on a discontinuous Percoll (Pharmacia-LKB, Uppsala, Sweden) density gradient, as reported.' In brief, cells were resuspended in a 100% Percoll suspension; four additional Percoll suspensions with 10% increment (60, SO, 40, and 30) were layered sequentially over the 100% fraction. Cells were spun at 3,000 rpm for I5 minutes. The 60% fraction of the gradient was used as a source of high density, small B cells'; the latter cells were further separated into CD5+ and CDS-B lymphocytes by immunomagnetic bead manip~lation.~
In some experiments, purified B cells were treated with a cytotoxic CD20 (Coulter) MoAb (discussed later) in the presence or absence of C' (low-toxicity rabbit complement; Cedarlane, Ontario, Canada)7 before being cultured.
Cc11 marker unalysis. The following MoAbs were used: CD 19, CDS, and CD3 from Becton Dickinson; CD14, CD.56, anti-HLA-DR, CD20, and CD23 from Coulter. A CD40 MoAb was kindly provided by Dr S.M. Fu (University of Charlottesville, VA). All MoAbs were used in indirect immunofluorescence with fluorescein isothiocyanate (FITC-conjugated sheep antimouse Ig) as second reagent (Dako, Glostup, Denmark). FITC-conjugated goat polyclonal antisera specific for human Ig H and L chains were obtained from Dako. The cells were fixed with 1% paraformaldehyde and analyzed by flow cytometry using a FACS analyzer (FACScan; Becton Dickinson). Controls were untreated cells, cells treated with the FITCsecond reagent alone, and cells treated with irrelevant isotypematched antibodies followed by the FITC-second reagent. ' In some experiments, the surface expression of G-CSFR by freshly isolated leukemic cells was investigated using phycoerythrin (PE)-conjugated G-CSF (R & D System, Minneapolis, MN) according to the instructions of the manufacturer. In brief, IO6 cells were incubated with 10 pL/mL conjugated cytokine for 60 minutes on ice. As control, another aliquot of cells was incubated as above with streptavidin-PE. Cells were then washed twice and resuspended in 0.2 mL phosphate-buffered saline for flow cytometric analysis.
Cell cultures.
Cell suspensions were cultured (1 X I 06/mL) in RPM1 1640 medium (Seromed-BiochromKG, Berlin, Germany) supplemented with L-glutamine, penicillin, and streptomycin, nonessential amino acids and 10% fetal calf serum (FCSj (Seromed) for the indicated times. Staphylococcus aureus Cowan I (SAC; Calbiochem, La Jolla, CA) (0.005% final concentration); phorbol myristate acetate (PMA, I O ' mol/L) and ionomycin (0.2 pg/mL) (Sigma Chimica, Milan, Italy); an insolubilized rabbit-antihuman IgM antiserum (BioRad, Milan, Italy) at the final concentration of 10 pg/mL; the CD40 MoAb at the final concentration of 10 pg/mL; recombinant (r) 1L4 (Genzyme, Milan, Italy; 10 ng/mL), IL-2 (Genzyme; 50 U/mL) or G-CSF (Amersham, Buckinghamshire.
UK; 10 pg to 10 ng/mL) were used as stimuli.
Proliferation of CLL B cells was tested by incubating 2 X IO5 cells/well in 96 well flat bottom plates (Coming, Staffordshire, UK) for 72 hours in the presence or absence of various stimuli. Cells were subsequently pulsed with 'H-thymidine (Amersham) for 16 hours and procured. Radioactivity was determined by liquid scintillation counting. Cell viability was assessed by Trypan blue staining.
Apoptosis. Purified B cells from B-CLL patients were cultured for S days in RPM1 1640 medium supplemented with 0.1% FCS. Cells were subsequently procured, penneabilized, and stained with propidium iodide (PI, Sigma; 50 pg/mL) according t o publishcd methods." The amount of DNA fragmentation was calculated by flow cytometric analysis." The results were exprevsetl ;I\ pcrcent apoptotic cells.
G-CSF ussay. Culture supernatants were collected at the indicated times and frozen at -80°C until tested. The presence of G-CSF was determined using an enzyme-linked immunosorbent assay (ELISA) (Amersham). The same assay, that has been calibrated to detect as low as 7.2 pg/mL G-CSF, was used to measure the cytokine in patient sera that had been stored at -80°C. In some experiments, granulocyte macrophage-colony stimulating factor (GM-CSF) was quantitated in culture supernatants by an ELISA kit from Amersham that detects a minimum of I .S pg/mL cytokine.
The biological activity of B-cell derived G-CSF was investigated by testing the colony stimulating activity (CSA) of G-CSF-containing culture supernatants in a bone marrow (BM) colony assay, as reported." Briefly, MNC were isolated from heparinized normal BM samples and cultured in 0.3% agarZZ with: ( I ) B-cell supernatants (10%' final dilution) in the presence or absence of specific neutralizing rabbit antisera to G-and/or GM-CSF (Genzyme) or of normal rabbit serum (NRS). These antisera were tested at concentrations 20-fold higher than those required to neutralize the maximum G-or GM-CSF amounts detected in CLL B-cell supernatants i n this and in a previous study," respectively; (2) rGM-CSF ( I O ng/mL. Genzyme) as a positive control; (3) medium alone as a negative control. Colonies were counted after 7 and 14 days in culture.
RNA cznu1ysi.r. Total cellular RNA was extracted according to Chomzynski and Sacchi" from B cells and the following control cells: the K562 cell line (negative control for G-CSF. G-CSFR. and GM-CSF mRNA); phytohemagglutinin (PHA)-stimulated normal PB MNC (positive control for G-CSF and GM-CSF mRNA); the U937 cell line (positive control for G-CSFR mRNA). The integrity and amount of each RNA sample were determined by staining the gel with ethidium bromide and visualizing it under UV light. For Northern blot analysis. RNA was size-fractionated in a I Tr morpholinopropanesulfonic acid formaldehyde (Sigma) agarose gel and transferred onto Hybond C extra membranes (Amersham) ah described.24 For hybridization, the probes were labeled by hexanucleotide primer method" with "P-dCTP (Amersham) as reported." The human G-CSF cDNA probe2h (kindly donated by Dr Steven Clark, Genetics Institute, Cambridge, MA) and the human G-CSFR cDNA probez7 (kindly donated by Immunex Corp, Seattle, WA) were isolated by restriction enzyme digestion and agarose gel electrophoresis. The glyceraldehyde-3 phosphate dehydrogenase (G3PDH) cDNA probe'" was supplied from Clontech (Palo Alto, CA).
For reverse transcriptase-polymerase chain reaction (RT-PCR) analysis, I @g of cellular RNA was reverse transcribed into cDNA by means of a commercial kit (Clontech) using oligo dT as primel-. Each complementary cDNA was then diluted to a final volume o f l00 pL and the efficiency of reverse transcription was evaluated by amplification of 10 pL of cDNA with the G3PDH primers supplied with the kit under nonsaturating conditions (1 minute 94°C. 1 minute 60T, 2 minutes 72°C for 25 cycles). Afterwards. for each PCR analysis. 10 p,L of cDNA were amplified in a SO pL reaction by adding 25 pmol/L of each specific primer and 2.5 U of Taq polymerase (Clontech).
The primers used, designed on the published sequences" '' with Oligo 4.0 program, were the following: G-CSF": forward TGTGC-CACCTACAAGCTGTGC; reverse CCCAGTTCITCCATCTGC-TGC. G-CSFR*': forward CCTCACAACCAGCAGCCTCATC; reverse TGCCGCCACCATGTGTCC. GM-CSF": forward ATC-TCTGCACCCGCCCGCTCG; reverse CCCTGCTTGTACAGCT-CCAGG.
The amplification profiles were: I minute at 94°C. 1 minute at 60°C. 2 minutes at 72°C cycles for both G-CSF and G-CSFR and 1
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RESULTS
I n vitro production of G-CSF by purijed B cells from B-CLL patients. B lymphocytes were purified from the PB of 30 B-CLL patients and cultured with or without SAC for 48 hours. Supernatants were subsequently tested for the presence of G-CSF by an immunoassay (Fig l) . In IS cases, G-CSF was detected in the supernatants of SAC-stimulated, but not of unstimulated, B cells (range I IO through 970 pg/ mL) (Fig I) . B cells from the 15 residual patients did not produce G-CSF at all.
As mentioned, the leukemic B-cell suspensions were on average 97% pure; the remaining cells were CD3' T lymphocytes. CD 16" NK cells, or CD 14' monocytes. Each of the latter cell types never exceeded 1 %. Nonetheless, additional experiments were performed to definitely exclude that the G-CSF detected in B-CLL cell supernatants was released by a contaminant cell. Purified B lymphocytes from two G-CSF producer CLL cases were incubated with a B-cell specific, cytotoxic CD20 MoAb, and C', the CD20 MoAb alone, C' alone or medium (control) before being cultured with SAC for 48 hours. Thereafter, supernatants were tested for the presence of G-CSF. In case one, the G-CSF concentration detected in the supernatant of control cells was 210 pg/mL, whereas that found in the supernatant of CD20 MoAb and C' treated cells was <7.2 pg/mL; in case two, the G-CSF concentration detected in the supernatant of control cells was 260 pg/mL, whereas that found in the supernatant of CD20 MoAb and C' treated cells was <7.2 pg/mL. In both cases, cells that had been treated with the CD20 MoAb alone or C' alone produced as much G-CSF as control cells (not shown). The finding that treatment with CD20 and C' abrogated G-CSF production unambiguously proved that the G-CSF producing cells were of B cell lineage.
The kinetics of G-CSF production by B cells from four CLL patients was subsequently investigated. Cells were incubated with SAC for various time intervals and G-CSF was assayed in the culture supernatants. The cytokine was first detected after 16 hours; its concentration increased after 24 hours, reached a plateau after 48 hours, and declined after 72-hour (Fig 2) . The observation that G-CSF amounts decreased in 72 hour supernatants raised the possibility that the cytokine bound to the cell surface (discussed later).
Thereafter, G-CSF gene expression in two CLL B-cell suspensions that had been tested for the kinetics of G-CSF release was investigated by Northern blot. Total RNA was extracted from cells cultured with or without SAC for various time intervals and hybridized to a G-CSF cDNA probe (Fig  3) . G-CSF mRNA was absent in freshly isolated cells, but was detected in SAC-stimulated cells. G-CSF transcripts were first observed after 8 hours (Fig 3, lane 3) in one case and after 16 hours (Fig 3, lane 10) in the other case. The intensity of the hybridization bands reached a plateau after 16 hours in the former case and after 24 hours in the latter case. In both cases, G-CSF mRNA seemed to disappear following 48 hours in culture (Fig 3) . Notably, however, when a more sensitive RT-PCR technique for G-CSF mRNA detection was employed, it was found that G-CSF transcripts persisted until 72 hours in both cases (data not shown). Finally, B-CLL cells that had been cultured without SAC did not express G-CSF mRNA at any time tested (data not shown).
Next, we investigated whether other stimuli were effective at inducing G-CSF production by those CLL B-cell suspensions that did not release the cytokine on incubation with SAC. Purified B cells from four CLL cases were cultured for 48 hours with: anti-p antibodies with or without rIL-2 or rIL-4; a CD40 MoAb with or without rIL-2 or rIL-4; rIL-2 alone; rIL-4 alone; PMA and ionomycin. Cell supernatants were subsequently tested for the presence of G-CSF. None of the previously discussed stimuli induced G-CSF release in any B-CLL case. In additional experiments, the possibility that G-CSF mRNA was expressed in the same cell fractions was tested by RT-PCR. No G-CSF transcripts were found in any sample following 24 hours incubation with the previously discussed stimuli (data not shown). Consistently with a previous report," all of these cell suspensions expressed GM-CSF mRNA, as assessed by RT-PCR analysis of 24 hour cultures performed in the presence of SAC (not shown).
In a subsequent series of experiments, five CLL B-cell suspensions that released G-CSF on exposure to SAC were tested for the ability to produce the cytokine following 24 hours culture with more physiologic stimuli than SAC itself anti-p antibodies with or without rIL-2 or rIL-4; the CD40 MoAb with or without rIL-2 or rIL-4; rIL-2 alone; rIL-4 alone. SAC-stimulated cultures were used as positive controls. with the CD40 MoAb and rIL-2 or rIL-4, respectively, triggered G-CSF release in amounts that were comparable to those induced by SAC (Fig 4) . In contrast. no G-CSF production was observed when CLL B cells were stimulated with the CD40 MoAb alone, rIL-2, or rIL-4 alone (Fig 4) . antiy antibodies alone, or associated with rIL-2 or rIL-4 (not shown). These findings indicated that not only SAC, but also a CD40 MoAb and cytokines were effective at inducing G-CSF production by a subset of leukemic B-cell clones.
In the individual B-CLL cases, no correlation was found between the ability of B cells to release G-CSF and patient age, disease stage. clinical manifestations, or previous treatments. The surface markers used for the characterization of B-CLL cells (such as, for example, CD5, CD23, and CD40) were expressed in the large majority of the cases. Therefore the immunophenotype did not provide any correlative information on the G-CSF producing capacity of the leukemic B-cell fractions.
G-CSF levels in B-CLL patient sera. Although CLL B cells produced G-CSF only on in vitro stimulation, the possibility that the cytokine was released in vivo in increased amounts was investigated. Sera from 14 B-CLL cases (9 G-CSF producers, S G-CSF nonproducers) were tested for the presence of G-CSF by an immunoassay; in all of the cases but one, the cytokine was undetectable. Patient 2. whose B cells produced G-CSF in vitro (see Fig l) , had high amounts of serum G-CSF (1.200 pg/mL) but did not display any distinctive clinical or laboratory feature.
Tonsillar CD5' B lymphocytes do not produce G-CSF.
CD5' B cells originate from the mantle zone of the secondary lymphoid follicles and represent the normal counterpart of most B-CLL proliferations." Therefore. we investigated whether CDS' tonsillar B lymphocytes did produce G-CSF in vitro. Resting B cells were isolated from tonsils on a Percoll density gradient and fractionated into CD5' and CD5-cells.'" These cell subsets were cultured for 24 to 72 hours with or without SAC and their supernatants were tested for the presence of G-CSF. No G-CSF was detected in supernatants from either unstimulated or SAC-stimulated CD5' or CD5-B lymphocytes. Furthermore, CDS' tonsillar B cells failed to produce G-CSF in response to the following The biological activity of G-CSF released by leukemic B cells was next investigated. BM MNC were cultured in agar with or without 3 B-cell supernatants that contained immunoreactive G-CSF in the presence or absence of a neutralizing rabbit antiserum to G-CSF or of NRS. Seven-and 14-day colonies were subsequently counted. Culture of BM MNC with Bcell supernatants and the anti-G-CSF antiserum resulted in a 50% reduction of 7-day (not shown) and 14-day (Fig 5) colonies as compared to the controls. Because SAC-stimulated CLL B cells produce GM-CSF," BM MNC were next cultured with B-cell supernatants and the combination of anti-G-and anti-GM-CSF antisera. Under these conditions, CSA was virtually abrogated (Fig 5) . Consistently with these results, the 3 CLL B-cell supernatants enriched for CSA ( Fig  5 ) were found to contain immunoreactive GM-CSF in the following concentrations: 186, 225, and 320 pg/mL, respectively. RT-PCR analysis showed the presence of GM-CSF mRNA in the corresponding cell suspensions (not shown).
These results show that the G-CSF produced by CLL B lymphocytes was biologically active and that the CSA released by the leukemic B cells was attributable to both Gand GM-CSF.
Freshly isolated CLL B cells express G-CSFR. As mentioned, the decreased concentration of G-CSF in 72-hour supernatants of SAC-stimulated CLL B cells suggested that the cytokine could bind to the cell surface.." To gain more insight into this issue, freshly isolated B cells from I 1 patients (7 G-CSF producers, 4 G-CSF nonproducers) were tested for the expression of G-CSFR mRNA by Northern blot. As shown in Fig 6A, B cells from 7 out of I I patients expressed G-CSFR transcripts; 5 of the latter cell suspensions produced G-CSF in vitro, whereas the 2 remaining cell fractions did not. Two of the 4 G-CSFR mRNA negative cases released G-CSF, whereas the other 2 did not. Next, we investigated whether G-CSF binding sites were expressed at the cell surface of the 7 CLL B-cell suspensions that expressed G-CSFR mRNA. Freshly isolated B cells were stained with PE-conjugated G-CSF and analyzed by flow cytometry. Figure 6B shows the results obtained in four representative cases; all of the cell suspensions (including the three not shown) bound fluorochrome-conjugated G-CSF, indicating the presence of surface receptors for the cytokine. The percentage of G-CSFR' cells ranged from a minimum of 47% to a maximum of 73% in the different cases. In contrast, the 4 CLL B-cell fractions that were G-CSFR mRNA-did not stain with PE-G-CSF (not shown). Furthermore, RT-PCR analysis of the latter cell suspensions failed to show any G-CSFR transcript (not shown).
The previously described experiments raised the possibility that binding of G-CSF to its receptors could induce functional changes in the leukemic cells. To clarify this issue, G-CSF related apoptosis' and proliferation of CLL B cells were studied.
First, leukemic B lymphocytes from the seven cases that expressed G-CSFRs were cultured for 5 days in low FCS medium with or without IO pg to IO ng/mL rG-CSF. Cells were then stained with PI and analyzed by flow cytometry. In three cases, spontaneous apoptosis observed in the control cultures was virtually abolished by incubating the leukemic B cells with 1 0 0 pg/mL rGCSF (Fig 7) ; lower and higher concentrations of the cytokine were ineffective (not ~h o w n ) .~ In the four remaining cases, no rescue of the leukemic cells from apoptosis was detected at any rG-CSF concentration. Second, B cells from the five B-CLL cases that produced G-CSF and expressed G-CSFR, were cultured with or without SAC and pulsed with 'Hfhymidine after 72 hours. None of the cell suspensions proliferated upon SAC stimulation; in contrast the same cell fractions displayed consistent proliferative responses to SAC and rIL-2" (and data not shown).
These findings indicated that endogenously produced G-CSF did not act as an internal mitogen.
In further experiments, the G-CSFR' B-cell fractions were cultured for 72 hours at various cell densities (from 2.5 X Io" to 1 X IO'/mL) and with a wide range of rG-CSF concentrations ( I O pg to IO ng/mL). Again. no proliferative responses were ever detected.
For Most of the experiments herein reported were performed using SAC as polyclonal B-cell activator. SAC has twG distinct binding sites for Ig, both of which involve staphylococcal protein A." The first site binds to the Fc fragment of IgG?' whereas the second one interacts with the third variable heavy (VH3) chain region of IgM," IgG, and IgA." Because of its binding capacity to the VH3 of most Ig isotypes, SAC has been recently designated as a B-cell superantigen.'* Furthermore, it has been proposed that SAC may stimulate B lymphocytes through additional mechanisms that are so far unknown.."
Although the data obtained with SAC clearly showed the ability of CLL B cells to produce G-CSF, the pathophysiologic meaning of such observation was obscure. Therefore, additional experiments were performed using anti-p or CD40 antibodies as physiologic B-cell activators: such stimuli were tested alone or in combination with rIL-2 or rIL-4. CLL Bcell suspensions that released G-CSF on culture with SAC also produced the cytokine following incubation with CD40 MoAb and rIL-2 or rIL-4. CD40 MoAb, rlL-2, or rIL-4 alone were ineffective. resulting in compartmentalized release of G-CSF.
The inability of anti-p antibodies to elicit G-CSF production by SAC-responsive CLL B-cell suspensions, even when tested in combination with rIL-2 or rIL-4, may be explained by defects in the signal transduction pathways related to surface IgM triggering.u,4s The same physiologic stimuli mentioned above (ie. anti-p or CD40 antibodies with or without cytokines) were applied to SAC-unresponsive CLL B-cell fractions. No G-CSF gene expression was ever detected, suggesting that these cell suspensions failed to produce the cytokine because of an intrinsic defect rather than to the nature of the stimuli they received.
Neither SAC nor anti-p or CD40 antibodies with or without cytokines. induced production of G-CSF in CDS' tonsillar B lymphocytes. The possibility that the latter cells are triggered to release G-CSF by stimuli other than those here employed cannot be disregarded. Nonetheless. the present findings would suggest that G-CSF synthesis in B-CLL cells is governed by mechanisms which. apparently. do not operate in their normal counterparts.
Supernatants from CLL B lymphocytes that released immunoreactive G-CSF promoted myeloid colony formation by normal BM progenitors. Neutralization experiments with specific antisera showed that such CSA was accounted for by the combination of G-and GM-CSF. These experiments provided evidence that B-CLL derived G-CSF was biologically active.
The expression of G-CSFRs on a subset of freshly isolated leukemic B cells was shown by the combined use of flow cytometry and Northern blot. In a l l of' the cases tested. the results obtained with the two methods were absolutely concordant. ie, G-CSFR mRNA" cell fractions always expressed G-CSF binding sites, whereas G-CSFR mRNA cases never stained with PE-G-CSF. Expression of G-CSFRs was unrelated to the ability of the CLL B-cell suspensions to release G-CSF in culture. The functional consequences of'the binding of G-CSF to its receptors on the surface of CLL B cells was investigated by testing proliferation and spontaneous apoptosis of the latter cells. Endogenously produced G-CSF did not serve a s an autocrine growth factor. Furthermore, rG-CSF did not exert any effect on the proliferation of CLL B cells over a wide range of cell and cytokine concentrations." In contrast. rG-CSF at the concentration of 100 pgl mL rescued G-CSFR' CLL B cells from spontaneous apoptosis in three of the seven cases studied. This rG-CSF concentration was previously found to be effective at rescuing normal GC B cells from apoptosis.' The reason why only a proportion of G-CSFR.' CLL B cells was rescued from programmed cell death by the cytokine is unknown and warrants further investigation.
In conclusion, this report shows that neoplastic B cells from a subset of B-CLL patients can be triggered to release G-CSF in vitro and that G-CSFRs may be expressed by fresh leukemic B lymphocytes independent of their ability to produce G-CSF. On the basis of our results, it may be hypothesized that, in vivo, G-CSF production takes place following bacterial"' or T-cell mediated stimulation of the leukemic B lymphocytes. B cell-derived G-CSF could be detrimental to the host by rescuing neoplastic lymphocytes from apoptosis in an autocrine or paracrine manner. This
For personal use only. on October 23, 2017. by guest www.bloodjournal.org From hypothesis may be supported by a recent case report showing that a patient with Richter's syndrome manifested a systemic lymph node enlargement while receiving treatment with rG-CSF for ne~tropenia.~' Neoplastic B lymphocytes from this patient were found to express G-CSFR mRNA. 47 Conversely, G-CSF produced by leukemic B lymphocytes might functionally activate neutrophils in the course of infectious episodes thus contributing to the clearance of the invading pathogens.
